Astec Lifesciences Limited

As of June 30, 2026, Astec Lifesciences Limited carries a market capitalization of 15.87B, placing it among publicly traded companies globally. Its enterprise value stands at 15.87B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Astec Lifesciences Limited's next confirmed earnings release is scheduled for October 26, 2026.

As of June 30, 2026, Astec Lifesciences Limited has 22.28M shares outstanding.

These figures are as of June 30, 2026.

These figures are as of June 30, 2026. The EV/Sales ratio of 3.47 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 15.87B versus a market cap of 15.87B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 6.43M in revenue per employee across its workforce of 712.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Astec Lifesciences Limited recorded an income tax benefit of -1.64M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -753.31M and -752.08M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Astec Lifesciences Limited's stock has declined approximately 3.96% over the past 52 weeks. The 50-day moving average sits at 664.03, while the 200-day moving average is 666.85.

Over the twelve months ended June 30, 2026, Astec Lifesciences Limited generated 4.58B in revenue and converted that into -752.08M in net income, yielding earnings per share of -34.77. EBITDA reached -6.00M, while operating income came in at -440.56M.

Over the twelve months ended June 30, 2026, Astec Lifesciences Limited posted a gross margin of 34.55, reflecting its pricing power and cost economics. The operating margin of -9.62 and net profit margin of -16.42 provide insight into operational efficiency.

Astec Lifesciences Limited's most recent stock split took place on July 4, 2025 with a 823:829 split ratio.